Skip to main content

Author: The Wistar Institute

The Wistar Institute’s NCI-Designated Cancer Center Named in Honor of Caplan Family’s Generous Support 

A gathering of Wistar employees, donors and senior leaders assembled outside The Wistar Institute on February 13th to unveil a new tribute to a family that has made an indelible impact on The Wistar Institute: Ellen and Ronald Caplan.  

With Ellen, Ron, and their son Matthew Caplan looking on, Dr. Dario Altieri, president and CEO of The Wistar Institute, removed a blue fabric drape to reveal the permanent sign, which reads “Ellen and Ronald Caplan Cancer Center.”  

The tribute was installed to recognize the Caplan’s principal gift for Wistar’s National Cancer Institute (NCI)-designated Cancer Center. Ron, who is the founder and president of PMC Property Group, Inc., and his wife Ellen made the gift to empower Wistar’s world-leading scientists in their search for high-impact discoveries toward promising cancer therapies. 

The Caplans have long-standing ties to Wistar. Ron has been a member of the Institute’s Board of Trustees since 2009, and in 2014, he and Ellen donated the 200-seat, high-tech Sarah and Matthew Caplan Auditorium in the Robert and Penny Fox Tower — named for their children in the hope that cancer’s cure would be found in their lifetime. As chair of Wistar’s Bold Science // Global Impact Campaign, Ron has contributed his leadership to help raise more than $50 million to power Wistar Science.  

During a reception following the unveiling, Dr. Altieri explained why philanthropy plays such an important role in advancing Wistar Science. “Wistar philanthropy is about the future — the promise and the hope for discoveries that have yet to be made,” he said. “We’ve learned science can transform the world, and we cannot be more grateful for people like the Caplans who have the vision to support that spirit of discovery.” 

Ron explained that his family has been directly impacted by cancer, and the gift is intended to help accelerate future discoveries that could lead to therapies and cures for the disease.  

“My son Matthew lost his grandmother to cancer when she was just 52. Today, she would have lived because of the great scientists that are here every day, trying to make the world a better place,” he said to a room full of Wistarians. “Ellen and I are thrilled that we’re able to make this gift to Wistar, and I’m honored that I’m lucky enough to be able to contribute to a place that is so wonderful.” 

The Wistar Institute Announces New Caspar Wistar Fellow, Dr. Irene Bertolini

Wistar scientist joins faculty to pursue research in breast and brain cancers

PHILADELPHIA—(Feb. 13, 2024)— The Wistar Institute, an international biomedical research leader in cancer, infectious disease, immunology, and vaccine development, is pleased to announce the recruitment of Irene Bertolini, Ph.D., to the Ellen and Ronald Caplan Cancer Center, where she joins Wistar’s Immunology, Microenvironment, and Metastasis Program as a Caspar Wistar Fellow.

Dr. Bertolini’s promotion to Wistar faculty is made possible by the Caspar Wistar Fellows Program, which supports outstanding junior scientists in the early stages of their careers as independent investigators. As a faculty member, Dr. Bertolini now runs her own laboratory, which allows her to pursue and develop her research interests in collaboration with Wistar scientists as well as biomedical researchers throughout the world.

“I’m both excited and grateful for the opportunity to join the faculty of The Wistar Institute as a Caspar Wistar Fellow,” said Dr. Bertolini. “I know first-hand the exceptional environment and resources that Wistar has to offer new investigators like me — I can’t think of a better place to start my lab.”

Dr. Bertolini is establishing the Bertolini lab to study the relationship between breast & brain cancers and extracellular vesicles, which are packets of biological materials that cells emit and exchange. Certain extracellular vesicles from cancerous cells can contribute to conditions that can promote cancer’s growth and spread, and Dr. Bertolini’s research program aims to characterize — and, ultimately, find a way to stop — the pro-cancer mechanisms of extracellular vesicles.

“Irene has been an invaluable member of my lab for years, so it is a special pleasure for me to watch her step up to the role of Caspar Wistar Fellow,” says Dario Altieri, M.D., Wistar president and CEO, director of the Ellen and Ronald Caplan Cancer Center, and the Robert and Penny Fox Distinguished Professor. “With years of experience and a love for her work, Dr. Bertolini will do the Wistar name proud. Her work on the tumor microenvironment and extracellular vesicles is an exciting contribution to Wistar’s cancer research, and I look forward to seeing what the Bertolini lab will accomplish.”

###

The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century, consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology. wistar.org

For a printable version of the press release, click here.

Wistar’s Jessie Villanueva, Ph.D., Receives ‘Diversity in Business’ Award

The Philadelphia Business Journal recognizes cancer scientist’s leadership in DEI

PHILADELPHIA—(Feb. 12, 2024)—Jessie Villanueva, Ph.D. — associate professor in the Molecular and Cellular Oncogenesis Program and associate director for Diversity, Equity and Inclusion in the Ellen and Ronald Caplan Cancer Center is one of the recipients of the 2024 Diversity in Business Award from the Philadelphia Business Journal.

The Diversity in Business Award is an annual distinction presented to select honorees from the Greater Philadelphia area who “are making strides in their own ways toward greater inclusion within the Philadelphia region’s workplaces.” Dr. Villanueva and her fellow honorees will be celebrated at a February 15th event at the Fitler Club in Center City, Philadelphia, and with a special February 16 issue commemorating their achievements in the Philadelphia Business Journal.

“It’s a tremendous honor to be among this year’s Diversity in Business Award winners,” said Dr. Villanueva. “I’m very proud of what we’ve accomplished at The Wistar Institute — Building on our culture of inclusive excellence, we are committed to shaping a biomedical research environment that incorporates diversity and inclusion across every facet, from the laboratory to the boardroom. Embracing an array of experiences ensures that diverse individuals contribute a myriad of perspectives, positioning us at the forefront of biomedical research. Together with every member of the Institute, we are shaping a future where diversity and inclusion fuel innovation.”

Since late 2019, Dr. Villanueva has served as the associate director of The Wistar Institute’s Inclusion Diversity, and Equity initiative. With staff from more than 20 countries from around the world, Wistar is building upon a foundational commitment to diversity, equity & inclusion.

“Jessie’s efforts are truly inspirational,” said Dario C. Altieri, M.D., Wistar president & CEO, director of the Ellen and Ronald Caplan Cancer Center and the Robert and Penny Fox Distinguished Professor. “We do not make scientific progress unless we have everyone at the table, and Jessie works to make sure both early-career and seasoned researchers from underrepresented groups can come to Wistar and make an impact. Jessie leads by example; she is a respected melanoma researcher with a research lab comprised of a diverse group of staff. We are very proud to see Dr. Villanueva receive this honor.”

The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century, consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology. wistar.org.

Wistar in the TV News: Scripps News story on National Black HIV/AIDS Awareness Day

Shining a spotlight on the need for an HIV cure during National Black HIV/AIDS Awareness Day

Wistar HIV researcher Dr. Luis Montaner spoke about his HIV cure research with Scripps News reporter Adi Guajarda for her National Black HIV/AIDS Awareness Day segment. The story shines a light on how HIV/AIDS is impacting the health of Black communities at a disproportionate rate. And how this negative effect—combined with stigma, racial discrimination and social determinants—leads to poorer health outcomes. The segment also pointed to hope and included an interview with Adam Castillejo, who is also known as the “London Patient” and is the second person in the world to be cured of HIV/AIDS. Adam became resistant to HIV after receiving a bone marrow transplant to treat Hodgkin’s lymphoma. 

Irene Bertolini, Ph.D.

Caspar Wistar Fellow, Molecular and Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center

Dr. Bertolini’s research focuses on investigating the role of extracellular vesicles in regulating cell-to-cell communication within the tumor microenvironment. Bertolini received her Ph.D. in Molecular and Translational Medicine at the University of Milan (Italy) in 2018. To pursue postdoctoral research, Bertolini moved to Philadelphia, where she joined Dr. Dario Altieri’s lab at the Wistar Institute. She was promoted to a staff scientist position, and in 2024, Bertolini accepted a position as a Caspar Wistar Fellow.

View Publications

The Bertolini Laboratory

215-898-3929

ibertolini@wistar.org

The Bertolini Laboratory

The Bertolini laboratory focuses on understanding the contribution of extracellular vesicles to shaping the tumor microenvironment and the metastatic niche in glioblastoma and breast cancer. In recent years, it has been shown that extracellular vesicles released by tumor cells and/or stromal cells may have a crucial impact on tumor progression and invasion. The Bertolini laboratory aims to elucidate their contribution to regulating immune infiltration and activation of resident stromal cells. In particular, Bertolini’s research is focused on (i) the role of microglia-derived extracellular vesicles in shaping the glioma tumor microenvironment and (ii) the contribution of extracellular vesicles released in hypoxic conditions by breast cancer cells to preparing the pre-metastatic niche.

Research

Determine the role of microglia-derived extracellular vesicles (EVs) in shaping the glioma tumor microenvironment (GME)

Glioblastoma (GBM) is the most common and aggressive tumor of the central nervous system, characterized by a highly complex and immune suppressive microenvironment. In the early stages, almost 40% of the total tumor mass is composed of tumor-associated microglia (TAMi). Despite considerable effort, the crosstalk between TAMi and tumor cells is poorly understood, and the mediators implicated in this response have not been identified. Preliminary data suggest that TAMi secrete EVs that play a critical signaling role between multiple cell types within the TME. Using combined in vitro and in vivo approaches, the Bertolini laboratory aims to unravel the contribution of TAMi-EVs in supporting glioma tumor growth and the maintenance of an immune-suppressive environment.

Investigate the role of hypoxia-derived EVs in breast cancer progression and metastasis

Breast cancer is one of the most common cancers in women worldwide. Intratumoral hypoxia is a major determinant of poor prognosis in breast cancer, independent of clinical stage at diagnosis. Previous studies (Bertolini I. et al., 2020, 2022, 2023) showed that EVs produced by breast cancer cells under hypoxic conditions can lead to tumorigenic transformation of normal epithelial cells in vitro and in vivo. Preliminary data showed that hypoxic-EVs prepare the pre-metastatic niche, inducing an increase in angiogenesis and generating an immunosuppressive phenotype. The Bertolini laboratory aims to dissect the role of hypoxic-EVs in shaping the pre-metastatic niche using in vivo and in vitro models of breast cancer. Moreover, the laboratory plans to investigate the EVs’ biodistribution in vivo.

Lab in the News

Selected Publications

  • Intercellular hif1α Reprograms Mammary Progenitors and Myeloid Immune Evasion to Drive High-Risk Breast Lesions

    Bertolini I, Perego M, Nefedova Y, Lin C, Milcarek A, Vogel P, Ghosh JC, Kossenkov AV, Altieri DC. Intercellular hif1α reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions. J Clin Invest. 2023 Apr 17;133(8):e164348. doi: 10.1172/JCI164348. PMID: 36892943; PMCID: PMC10104898. 

  • NFκB Activation by Hypoxic Small Extracellular Vesicles Drives Oncogenic Reprogramming in a Breast Cancer Microenvironment

    Bertolini I, Perego M, Ghosh JC, Kossenkov AV, Altieri DC. NFκB activation by hypoxic small extracellular vesicles drives oncogenic reprogramming in a breast cancer microenvironment. Oncogene. 2022 Apr;41(17):2520-2525. doi: 10.1038/s41388-022-02280-3. Epub 2022 Mar 30. Erratum in: Oncogene. 2023 Feb;42(9):708. Erratum in: Oncogene. 2023 Jun;42(27):2195. PMID: 35354906; PMCID: PMC9040905.

  • Small Extracellular Vesicle Regulation of Mitochondrial Dynamics Reprograms a Hypoxic Tumor Microenvironment

    Bertolini I, Ghosh JC, Kossenkov AV, Mulugu S, Krishn SR, Vaira V, Qin J, Plow EF, Languino LR, Altieri DC. Small Extracellular Vesicle Regulation of Mitochondrial Dynamics Reprograms a Hypoxic Tumor Microenvironment. Dev Cell. 2020 Oct 26;55(2):163-177.e6. doi: 10.1016/j.devcel.2020.07.014. Epub 2020 Aug 10. PMID: 32780991; PMCID: PMC7606608.

View Additional Publications

Continue reading

Wistar in the News: Technical.ly Philly story on Biomedical Technician Training Program’s Latest Iteration

Philly orgs are partnering with a gene therapy manufacturing company for this new workforce development cohort

The Wistar Institute was featured in Technical.ly Philly for news of its “Biomedical Technician Training Program: Lab Technician. This is the latest iteration of a 24-year-old reskilling initiative to get Philadelphians into life science jobs”, by reporter Sarah Huffman.

A coalition of life science organizations are partnering to continue a workforce development opportunity for underemployed Philadelphians interested in the field. The Wistar Institute, West Philadelphia Skills Initiative (WPSI), Philadelphia Industrial Development Corporation (PIDC) and the Chamber of Commerce for Greater Philadelphia have enlisted cell and gene therapy manufacturing company VintaBio for the Biomedical Technician Training Program: Lab Technician, they announced last week.

Read full Technical.ly Philly story here.

Wistar Institute is opening a new center to research vaccines that could treat and prevent cancer

The Center for Advanced Therapeutics is intended to position Wistar as an appealing research partner for pharmaceutical companies.

The Wistar Institute, a National Cancer Institute-designated research center in Philadelphia, plans to open a new…


The Wistar Institute was featured in The Philadelphia Inquirer for news of its creation of a Center for Advanced Therapeutics, by reporter Sarah Gantz.

Committed to advancing research discoveries that lead to new solutions to global health, Wistar will expand its focus to cancer, infectious disease and translational research to accelerate the development of novel therapeutics. Read full Inquirer story here.

If you do not have an Inquirer subscription story may be behind a paywall.

From The Philadelphia Inquirer. ©2023 Philadelphia Inquirer, LLC. All rights reserved. Used under license.

PCOM, The Wistar Institute Announce Innovative Biomedical Sciences Collaboration

In a move designed to advance opportunities for students to expand their access to cutting-edge research and education in the field of biomedical sciences, Philadelphia College of Osteopathic Medicine (PCOM) and The Wistar Institute have announced an academic collaboration to offer degree programs, courses and other educational opportunities to students at each institution.

“I am thrilled about this collaboration,” said Gregory McDonald, DO ’89, dean of the School of Health Sciences at PCOM. “Wistar has a long track record of effective and relevant education programming that prepares students for success, so to be able to offer courses like ‘Life Science Innovation’ to biomedical sciences students starting next year is an exciting opportunity.

“PCOM’s commitment to educating tomorrow’s biomedical leaders through diverse educational programs is perfectly aligned with The Wistar Institute’s goal of exposing students to authentic training opportunities,” said Kristy Shuda McGuire, Ph.D., Dean of Biomedical Studies at Wistar. “This collaboration will provide students with the foundational knowledge and the hands-on training they need to successfully pursue careers in the ever-advancing field of biomedical science.”

“PCOM’s collaboration with The Wistar Institute offers our students tremendous opportunities to integrate and apply their knowledge of clinically relevant basic science to drug and vaccine development and validation, and the process of bringing a product to market,” said Mindy George-Weinstein, Ph.D., PCOM’s Chief Research and Science Officer. “The agreement also has the potential to lead to inter-institutional research collaborations.”

The collaboration brings together PCOM, renowned for its commitment to educating students in holistic health with an emphasis on evidence-based practice and The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease. As part of the agreement, trainees at Wistar will have access to PCOM’s foundation year biomedical science curriculum. In addition, students enrolled in PCOM’s Biomedical Sciences program will have access to courses in the rapidly evolving fields of Cancer Biology, Vaccines and Immune Therapies, and the option to pursue a concentration in Translational Life Sciences. Excitingly, this concentration will be available to students at all three PCOM campuses. Both institutions also recently received grant funding to implement the new courses and for student travel to Wistar for their annual “Shark Tank” presentation and event.

PCOM will also offer adjunct status to some Wistar faculty, with PCOM faculty offered reduced rates for shared resource services at Wistar.

This collaboration is intended to foster an environment where students can explore, learn, and contribute to the cutting-edge fields of biomedical research and life sciences. PCOM and The Wistar Institute hope to use this collaboration as a model to develop additional collaborative educational opportunities in the future.

Media Contacts:

Daniel McCunney
Associate Director, News & Media Relations
Philadelphia College of Osteopathic Medicine
267-449-1360
danielmc1@pcom.edu

Darien Sutton
Director of Media Relations, Communications & Marketing
The Wistar Institute
dsutton@wistar.org

###

About Philadelphia College of Osteopathic Medicine
For the past 125 years, Philadelphia College of Osteopathic Medicine (PCOM) has trained thousands of highly competent, caring physicians, health practitioners and behavioral scientists who practice a “whole person” approach to care—treating people, not just symptoms. PCOM, a private, not-for-profit accredited institution of higher education, operates three campuses (PCOM, PCOM Georgia and PCOM South Georgia) and offers doctoral degrees in clinical psychology, educational psychology, osteopathic medicine, pharmacy, physical therapy, and school psychology. The college also offers graduate degrees in applied behavior analysis, applied positive psychology, biomedical sciences, forensic medicine, medical laboratory science, mental health counseling, physician assistant studies, and school psychology. PCOM students learn the importance of health promotion, research, education and service to the community. Through its community-based Healthcare Centers, PCOM provides care to medically underserved populations. For more information, visit pcom.edu or call 215-871-6100.

About The Wistar Institute
The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century, consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology. wistar.org.

Dr. Louise Showe Reflects on 40 Years at Wistar

Enter Dr. Louise Showe’s office, and you’ll see the evidence of a life lived at the intersection of family and science. A photo taken by her son of a Florida panther hangs on her door. Drawings from her grandkids are tacked prominently above the credenza or sit nestled on her desk, perched amongst binders of research data and stacked manilla folders. The walls are adorned with abstract paintings and black-and-white photos. A pastel-colored vase sits on the windowsill, overlooking The University of Pennsylvania’s Cohen Hall in the background. This is clearly an office that has developed a unique personality, one that has been curated by the woman who has inhabited it for the bulk of her career at Wistar.

A career, it turns out, that wasn’t even part of her plan.

Dr. Showe arrived at Wistar somewhat by chance, after a random phone call she received in 1983 from The Wistar Institute.

“I was working at CHOP, and the phone rang. When I picked it up this voice on the other end said, ‘would you like a job?’ And I said, ‘I already have a job!’,” she recalls, laughing.

And now, 40 years after that fateful call, Dr. Showe has finally decided the time is right to hang up her lab coat and retire from The Wistar Institute.

A skill in demand

In 1975, Dr. Louise Showe received her graduate degree in Biology from the University of Pennsylvania, before venturing to Basel, Switzerland and the Biozentrum der Universität Basel for her postdoctoral work. While in Switzerland, she focused on researching bacteriophage – viruses that infect and replicate in bacteria cells – and brought that expertise back to Penn, and eventually to Children’s Hospital of Philadelphia.

When she received the unsolicited job offer to join Wistar, she had been working as a researcher in the Hematology department at CHOP for only 8 months, having moved there from the University of Pennsylvania. But that research background in bacteriophage development had given her the experience Wistar needed to clone and characterize genes including those rearranged genes involved in chromosomal translocations evident in a variety of cancers. “The Wistar Institute specifically sought me out because it had the tools to map these chromosomal rearrangements, but did not have the expertise needed to clone them,” she explains. “At that time the only laboratories successfully doing genomic (gene) cloning were laboratories who knew how to manipulate bacteria and bacteriophage to make the reagents that you needed to perform that cloning.”

It took some time to convince her that Wistar was the ideal place for her research, but in the end, the institute won out. “The science at Wistar was so exciting, and it fit in very well with my expertise and my goals,” she recalls. “I also liked the size of Wistar, the administrative support and the ability to interface with all levels of the organization. It was an environment where I felt I could make an impact and change things.”

So, in 1983, Dr. Showe left CHOP and joined Wistar, bringing with her a rigor that surprised some people.

“The first thing I did was check all the benches in the lab to make sure they were level,” she explains. “They thought I was crazy, but when you’re screening the libraries [of bacteriaphage], they’re on these small agarose plates. If the benches aren’t completely level, it can really mess up the screening process.”

In fact, it wasn’t long before Dr. Showe determined why Wistar had been having such trouble performing genetic cloning in the first place. “They had invested in automated washing systems to clean the glassware, but it left some sort of residue that affected the bacteria enough that they couldn’t successfully grow the bacteriophage,” she explains. “We had solved that problem while I was in the lab in Switzerland. I had them immediately install a glass still to make the water for preparing the growth medium and start hand washing and sterilizing any glassware used to generate the cultures and extracts needed for the genomic cloning.”

A family affair

As a working parent of three children – one daughter and two sons – Dr. Showe was thoughtful about how her working life may impact her home life. In an era when the working world wasn’t always sympathetic to the demands of family – especially for women – she was conscious of finding a balance that would work.

“I had taught at Haverford college for six years, so I understood the requirements of that position. I knew that if I went into academia, I would have to teach and do research while trying to balance a family,” she explains. “I felt I couldn’t handle all three. I really loved the research and decided that I had to try to make a go of it.”

Juggling the two also had its challenges. She reflects on one instance when she was running late to pick up her daughter from daycare near Valley Forge Park where she lived.

“I can remember arriving at a closed daycare, and my daughter was sitting on the curb with one of the staff members, waiting for me” she recalls. “There was no happy face! When I think of it now, I laugh, but it was a challenge at times. I swear to this day my daughter still brings that up.”

An evolving career

Since first joining the institute, Showe has seen five directors and many changes at Wistar, but it’s still clear she loves her science and the impact she’s made here.

“I’ve always been really interested in developing technology,” she admits, “and I get a lot of satisfaction from doing that and seeing other people use those technologies to solve other problems.” In fact, Showe founded the Genomics Core at Wistar in 1995 and formed the first bioinformatics group in her lab to help understand that genomics data.

Dr. Showe has spent the latter part of her career developing biomarkers to predict whether a lung nodule detected by CT scan is benign or malignant based on gene expression in a simple blood sample. Reflecting on the work, she says, “the lung cancer work was a big challenge and whatever happens I think we’ve contributed to the expanding interests of using signals in peripheral blood to understand a variety of bio-medical problems.”

It’s that kind of problem-solving that has kept Dr. Showe engaged in her work. “When I go to sleep at night, I’m still trying to work out problems in my head,” she continues. “I’ll ask myself, ‘What am I missing?’ So, quitting has been complicated – there are not many 83-year-olds in the Institute and it is certainly not necessarily the best path to take.”

That vast knowledge and institutional memory have been a benefit to younger colleagues, who see Dr. Showe as a mentor. “I meet frequently with many young researchers,” she says “I’ve always told them you have to pick your battles and never make it personal. You can speak your mind, but you have to decide what’s really important and put your focus there.”

When asked what she’ll do once she’s no longer in the lab, Dr. Showe chuckles and explains that her daughter has been asking that question for quite some time. “‘Do you have a plan Mom?’ Well, we’re still thinking about what’s next, but I don’t think I’ll be sitting around knitting.”

Pancreatic Cancer Survivor and Pancreatic Cancer Advocate Meet Wistar Scientist Focused on Research Advances

Wistar’s Dr. Rahul Shinde with PanCAN’s Nick Pifani and Bruce Platt Rally Around Common Bond

Meet Nick Pifani who came to Wistar to share his story of surviving pancreatic cancer; he was one of several in his family who faced pancreatic cancer and won the battle. Bruce Platt, PanCAN volunteer advisory board member, lost his mother to pancreatic cancer. Nick and Bruce met Wistar’s Dr. Rahul Shinde, a 2022 PanCAN Career Development Award recipient, to learn more about his promising pancreatic cancer research.

“We want to tell the great stories—about the doctors that save lives and the researchers that ultimately bring new drugs, therapies and standards of care to patients,” said Nick. “We also want to tell positive stories of survival.”

Nick and Bruce are Philadelphia ambassadors for the local PanCAN cause, they connect cancer survivors with resources while building awareness and understanding. Pifani and Platt both see the need for a paradigm shift on how patients process a pancreatic cancer diagnosis as well as help the public to understand that pancreatic cancer can be treated effectively.

“My mother was diagnosed in 2004. I became a caregiver in 2006. She passed in 2009—she almost made five years,” said Bruce. “Back then, there were no real treatment options. The doctor basically said to my mother, ‘Go get your affairs in order,’—can you imagine the shock of that?”

When Bruce’s mother passed, he wanted to be her voice and in 2010 went to his first PanCAN meeting. Every year he’s become more involved. Bruce’s passion for the cause led to political action and making headway on pancreatic cancer awareness and support with legislators like Congressman Brendan Boyle and U.S. Senator Bob Casey. Along the way Bruce met many people diagnosed and fighting pancreatic cancer who ultimately became his friends. “I’ve met and become close to amazing people, but you can also get to a point where you think, I’ve done everything I can do. But if I ever get near that point, someone usually calls me and says, ‘So-and-so has it’ and it pumps me back up. So, I go back and fight some more. I’m in this until the day I die.”

When Nick was diagnosed with pancreatic cancer he wasn’t interested in the standard of care. “I knew what the standard of care did for about everybody else and I didn’t want to go down that route because I knew where it would end. Fortunately for me, I had doctors who found genetic mutations and understood I would have better success with different types of chemotherapy and radiation.”

Nick’s hope is that research and treatments progress to where a person diagnosed with pancreatic cancer has more options. “The disbelief and horror that happens when you are diagnosed, will be followed with, ‘We have four different treatment options, they’re effective and have an 80% or 90% cure rate. Which flavor do you want?’ Hopefully, Bruce and I will be around to see that.”

That day isn’t here yet, but Wistar scientists are working to make it happen. Nick and Bruce met with Dr. Rahul Shinde, one of Wistar’s resident pancreatic cancer researchers.

Dr. Shinde’s research is in one of the hottest areas of science and focuses on how the gut microbiome impacts immune cell function — those immune cells’ ability to fight cancer. He hopes to pave the way for future gut-bacteria-based therapies in the hopes of improved pancreatic cancer patient survival.

Dr. Shinde studies how macrophages — specialized cells that act as a front-line defense system for our immune systems — alter the pancreatic cancer tumor microenvironment which plays a key role in how the cancer develops, progresses, and reacts to therapies. “The successful outcome of this research may form the basis for gut bacteria-based therapies or diet-based therapies to improve the survival as well as the quality of life of pancreatic cancer patients,” he said.

“If you’re going to get sick, Philadelphia is a good place to be because we have the best doctors and researchers in the world,” said Bruce. “I have a big mouth. I’ll fight for more and more research money and more and more exposure. Did you know Jack Benny, Joan Crawford, Michael Landon, Patrick Swayze, Steve Jobs, and Alex Trebek all died of pancreatic cancer? My mother always said we need to get a celebrity behind us to tell this story. I don’t plan to quit telling all the stories I have anytime soon.”